Try our Advanced Search for more refined results
Life Sciences - October, 2012
249 articles
- SigmaPharm Looks To Relaunch Skelaxin Antitrust Battle
- FDA Seems Unlikely To Move Hydrocodone To Stricter Class
- FDA Should Use Foreign Oversight For Food Imports, GAO Says
- Ex-Orthofix Sales Manager Pleads Guilty To Medicare Fraud
- Suspension Of Novartis Flu Vaccines Lifted In 2 Countries
- Pharmacy Recalls All Drugs Amid Meningitis Outbreak Probe
- FTC To OK Corning's $730M Labware Buy, With Conditions
- Stryker Again Seeks To Block Exec From Jumping To Zimmer
- Inspiration Biopharmaceuticals Files For Ch. 11, Seeks Buyer
- Look Before You Leap Into A Securities Litigation Trap
- Cephalon Faces Class Cert. Bid In Actiq Marketing Row
- Diet Supplement Maker SEI Dodges DMAA Class Action
- Muslim Woman's Vitamin Label Claims Preempted, Judge Says
- Biogen Challenges USPTO Patent Term Adjustment Policy
- Donut Hole Drug Prices Kept In Check By ACA, Report Says
- Stem Cell Co. Says Rival Infringed Blood Product Patents
- Peregrine Sued By Investors Over Cancer Drug Claims
- Nutraceutical Can't Shake 'Yummi Bears' Trademark Claims
- Novartis Inks $20M Deal To End Texas Medicaid Fraud Suit
- 7 Tips For Avoiding False Claims Act Whistleblower Suits
- 2 In Federal Zoloft MDL Want Case Kicked Back To Calif.
- Sullivan Steers Bayer's $1.2B Schiff Nutrition Buy
- Opportunities And Challenges Of Telemedicine
- NIH Should Open Patents For Abbott HIV Drug, Petition Says
- CAFA Provides Wide Removal Power, NAM Tells High Court
- Banana Boat Sunscreen Ads Are Misleading, Class Says
- Bar Association Asks Fed. Circ. To Clarify Role On Obviousness
- Caldera Fails To Escape J&J Pelvic Mesh MDL Claims
- Stryker Sues Zimmer, Ex-Employee Over Trade Secrets Breach
- NJ Judge Won't Reconsider Tossing Shareholder's Vioxx Suit
- Watson Sheds Rugby OTC Drug Line In $117M Deal
- Stanford, Prenatal Blood Test Co. Say Rival Infringes Patent
- New Zealand Warns Of Zimmer Hip Implants' Early Failure
- Dietary Supplement Marketers Now Under OIG Scrutiny
- BioTech Firm Says Heller Ehrman Patent Gaffe Cost It $100M
- Meningitis Outbreak Exposes Oversight Failures, Markey Says
- Canada Pulls Novartis Flu Vaccines Over Safety Concerns
- Omeros Can't Exclude NIH Testimony From Ex-CFO's FCA Suit
- J&J OK'd To Proceed With Investor Deal In Compliance Row
- Fed. Circ. Won't Review USPTO, Court Split On Validity
- FDA Finds Sanitation Lapses At Pharmacy Linked To Outbreak
- Novartis Given Reprieve In Elidel FCA Suit
- Gene Sequencer Says Ex-Partner's $138M Deal Broke Promises
- AmerisourceBergen, Pharmacy At Draw In $106M Contract Row
- Cincinnati Fights Coverage of W.Va. AG's 'Pill Mill' Suit
- FDA Halts Distribution At 2 Supplement Makers
- Evanston Seeks To Escape Coverage Of Fungal Dye Suits
- Teva, GSK Face Another Suit Over Generic Lamictal Deal
- Romney Could Give Health Cos. Raked By Probes Willing Ear
- GSK Targeted In Antitrust Suit Over Drug-Discount Program
- Forest Lab Settles Bystolic Patent Row With Generic Drugmaker
- In Support Of Learned Intermediary Doctrine
- Merck Can't Shield Testimony Docs In NuvaRing MDL
- St. Jude Escapes Volcano's Patent Claims Over Heart Device
- Pfizer Won't Face Retrial In Premarin Breast Cancer Suit
- St. Jude Investors Win Class Cert. In Stock Fraud Suit
- Pfizer, Ranbaxy Can't Pause Lipitor Pay-For-Delay Suit
- Boehringer Pays $95M To Settle FCA Suit Over Drug Marketing
- Glaser Weil Guides OpenGate's Purchase Of Thermo Fisher Unit
- Branded Drug Cos. Not Liable For Generics, 5th Circ. Rules
- Medtronic Manipulated Bone Device Studies, Report Says
- Bayer Can't Escape Employee's FCA Retaliation Suit
- Simpson Thacher Aids McKesson In $2.1B Medical Supplier Buy
- A Growing Problem For Multinational Pharmas
- Resistance May Be Pharmacy's Best Bet In Meningitis Probe
- PE Firm Wants Out Of Class Deal To Sue Celera Over Buyout
- Lawmakers Release New Drug Track-And-Trace Proposal
- Ore. Lands $4M Settlement In McKesson Drug Pricing Case
- NJ Courts Mull Centralized Stryker Hip Implant Litigation
- CORRECTED: DC Anti-SLAPP Law Preempted In 3M Blackmail Suit, Judge Says
- Pfizer, Bayer, J&J Push Phony Expiration Dates: Class Suits
- Insurer Asks Supreme Court To Stop 'End Run' Around CAFA
- Generic Pharmaceutical Liability: Challenges And Changes
- GSK, Teva Can't Put Brakes On Pay-For-Delay Challenge
- K-V Takes Fight Over Makena Knockoffs To ITC
- FDA Warns Alere Over Weak Response To Manufacturing Errors
- AstraZeneca Affiliate Running Factory Cleanup Enters Ch. 11
- Roche Faces Potential Fine In EU Safety Probe
- Wash. Judge Won't Stop Actos Generic For Mylan Appeal
- Antitrust Experts See 2 Front-Runners For Sen. Kohl's Post
- Wyeth Says 3rd Circ. Appeal Stays Philly Fen-Phen Trial
- Pharmacists Push Pa. Gov. To Sign Pharmacy Choice Bill
- House Expands Probe Into Deadly Meningitis Outbreak
- Bayer Calls False Ad Class Actions Over Probiotics Flimsy
- Medical Body Area Networks: Promising Yet Risky
- How To Get The Most Out Of Your Statistical Sampler
- Abbott, Other Stent Makers Seek Toss Of Off-Label FCA Suit
- U of Calif. Breached X-Ray Licensing Deal, Caldera Says
- K-V Pharma Reaches $7.5M Deal With Zydus Pharma
- Guidant Pushes US To Prove FCA Claims Aren't Resolved
- Purdue's OxyContin Patent Suit Survives Dismissal Bid
- Meningitis Probe Could Cause Drug Shortages, FDA Says
- Volcano Didn't Infringe St. Jude Device Patents, Jury Says
- CORRECTED: Gore Asks Justices To Review Joint Inventor Standard
- Judge Orders FDA To Approve Watson's Generic Actos
- In ADHD Play, Pfizer Inks $700M Deal For NextWave Pharma
- Liability Claims In Pa. Prevacid Suit Pared, Punitives Allowed
- Complying With HIPAA: A Blur For Health Tech Cos.
- Another Case Highlights Ambiguity Of Pharma Liability
- Legal Industry Trends: Lawyer Salaries And Job Growth
- Feds Can't Ignore Rulemaking Comments, Supreme Court Hears
- Hunton & Williams Hires Charlie Crist's Ex-GC In Miami
- Trade Secrets — Less Risky Under AIA Prior User Rights?
- Powerful House, Senate Panels Set For Election Year Shake-Up
- FDA Panel Recommends Approval Of Genzyme's Kynamro
- European Regulators Reject Vivus Obesity Drug Used In US
- Omnicare Whistleblower Can't Revive Tainted Drugs Claims
- Sen. Urges Crackdown On Misleading Power Wheelchair Ads
- OTC Drug Distributor Sues Contract Manufacturer Over Recalls
- Smith Gambrell Picks Up Ballard Spahr Technology Patent Pro
- In The FDA Crosshairs: Composite Scores In Drug Ads
- A View From Inside The Litigation Finance Market
- Meningitis Suits Stand To Benefit From FDA Criminal Probe
- Ferring, Aventis Trim Claims In DDAVP Antitrust Class Action
- Smith & Nephew Urges Fed. Circ. To Rethink Jury IP Findings
- US Slams Jailed Supplement Maker's Bid To Duck $450M Fine
- Pa. Judge To Rethink Delay In Wyeth Fen-Phen Trial
- The Cure For Calif.'s Food Suit Binge
- Pfizer Settles 1st Trial In Chantix Suicide MDL
- Cooley Closes 2nd Life Sciences Deal In 2 Days
- Ex-Sales Reps Challenge J&J Unit's Noncompete Deal
- Gene Sequencer's Investors Say $118M Deal Chilled Other Offers
- Medtronic Says Fed. Circ. Botched Burden-Of-Proof Analysis
- Pfizer Says Copay Subsidies Don't Harm Benefit Funds
- Illumina Patent Claims Invalidated In DNA Sequencing Row
- Vinson Scores Ex-Dickstein Shapiro Patent Pro In DC
- Franck's, FDA Seek To Drop Compounding Oversight Case
- Meningitis Victim's Widow Targets Drug Compounder
- Kelley Drye OK'd To Rep Ciba, Ex-Workers In Injury Row
- Arch Chemicals Faces Age-Bias Suit Over Post-Merger Layoffs
- Tricare Price Caps Unfair To Pharma Cos., DC Circ. Hears
- 4 Key Issues In Launching A Global Telemedicine Program
- Walgreen Says Insurer Owes It $3M For Avastin Defense
- Pfizer Fails To Delay Chantix Trial Despite New Study
- Give FDA More Data On Antibiotics In Livestock, Rep. Says
- OIG Urges Medicaid To Lower Drug Payment Limits Quickly
- FDA Questions Safety Of Genzyme's Kynamro
- Pharmacy Linked To Meningitis Outbreak Faces $15M Suit
- JPML Won't Centralize Gerber Baby Formula Suits
- 7th Circ. Lets Abbott Combine, Transfer Depakote Cases
- Ex-Purdue Execs Ask DC Circ. To Revisit HHS Ban Case
- UVA Whistleblower Nets Award In FCA Suit Over Health Grant
- Having One's Cake And Eating It Too In Post-Grant Review
- FDA Warns Avon Over Wrinkle-Product Marketing
- Sealing The Deal: Weil Races To Finish In $2.6B Medicis Sale
- Watson Gets FTC Nod For $5.5B Actavis Buy, With Concessions
- Obama, Romney Throw Blows Over Energy, Health Care, Trade
- Ear Candler Loses Cert. Bid In Suit Over FDA Warning Letters
- 2 More Drugs May Be Linked To Meningitis Outbreak, FDA Says
- CVS Pays $5M To End Whistleblower's Medicare Fraud Claims
- Extra Damages Bid In $22M Stent Suit Denied By Fed. Circ.
- Forest Targets Docs' Testimony In Lexapro, Celexa Suicide MDL
- Post-Meningitis Outbreak: Questioning FDA's Oversight
- Ranbaxy Wants In On Mylan's Suit Over Valsartan Exclusivity
- Allergan's Sanctura IP Appeal Turned Away By High Court
- Clifford Chance Guides Cinven's $589M Pharma Co. Buy
- Meningitis Plaintiffs Face Uphill Battle If Pharmacy Fails
- ITC To Probe Gnosis, Macoven's Folate Dietary Products
- House Meningitis Probe Sets Sights On State Pharmacy Board
- Questcor Execs Hid Athcor Woes To Pad Price, Suit Says
- Fed. Circ. Upholds $31M Win In Hearing Aid IP Suit
- AstraZeneca, Sandoz Dodge $30M Medicaid Fraud Verdicts
- Pfizer Asks 11th Circ. To Block CEO's Chantix MDL Testimony
- Meningitis Outbreak Spurs Push For Compounder Crackdown
- NIH Says Better Animal Studies Will Speed Drug Development
- Novartis Eye Drug Doesn't Infringe Rival's IP, UK Court Says
- Walgreen Fights Shipping Center's DEA Suspension At DC Circ.
- Womble Carlyle Snags Ex-Connolly Bove Patent Litigators
- GSK To Make Trial Data Available To Researchers
- Wyeth Loses Bid For Stay In Philly Fen-Phen Trial
- Fed. Circ. Denies Roche's Bid To Halt Boniva Generics
- Purdue Sues To Halt Sandoz's Generic OxyContin Plans
- Presidential Panel Calls For Gene Sequencing Privacy Rules
- 9th Circ. Targets Claims That Nidek Misused Lasik Beams
- Meningitis Outbreak Exposes FDA's Oversight Failures
- Fla. Hospital Wants Class Cert. In $867M Drug Antitrust Suit
- 1st Circ. Revives Fired Ex-Lax Plant Worker's Age Bias Suit
- Bausch & Lomb, Akorn Warned Over Unapproved Eye Drugs
- AAIPharma Gets Claims Slashed From Darvocet MDL
- Mylan Settles Dispute Over Generic Orapred ODT
- Sunshine Overseas: Transparency Rules For Life Sciences
- Merck Ordered To Turn Over Docs In Vioxx MDL
- K-Dur Applies To Authorized Generic Deals, FTC Insists
- Pharmacy Group Floats Plan To Save US $100B In Drug Costs
- Hill Seeks Probes, More Oversight After Drug-Caused Meningitis
- Dilworth Taps Ex-Saul Ewing Atty To Lead Health Care Practice
- Arnold & Porter Hires Pharma Industry Advocate In DC
- Pfizer Inks $164M Settlement In Celebrex Securities Suit
- Sanofi, Merck JV Recalls Faulty Typhoid Vaccine, UK Says
- Advice For Controlling Stockholder In 3rd-Party Merger
- Avanir Targets Impax Over Generic Nuedexta Plans
- FTC's Androgel Case May Not Be Best To Tackle Pay-For-Delay
- Druggists Say NY Medicaid Mail-Order Plan Harms Competition
- Saul Ewing Lures Patent, Biotech Atty From Cozen O'Connor
- Lawmakers Ask DEA For Clearer Policies On Pharmacy Supplies
- HMO Asks 1st Circ. To Uphold $142M Neurontin Verdict
- Pfizer Vows Appeal After India Revokes Sutent Patent
- Novartis Defeats Aredia-Zometa Suit Over Jaw Damage
- ANI, BioSante To Merge In $95M Stock Deal
- What The Supreme Court's Amgen Decision Will Mean
- EU OKs $5.2B Watson-Actavis Tie-Up
- 3 Ways To Make Your Next Deal Better, Faster, Cheaper
- Becton Dickinson Infringed 4 Hologic Patents, Judge Finds
- Deadly Outbreak Puts Compounded Drugs In FDA's Crosshairs
- Teva, Impax To Pull Generic Wellbutrin After FDA Finding
- FTC Takes Androgel Pay-For-Delay Case To High Court
- New Data Rescues Zymar Patent, Allergan Tells Fed. Circ.
- FTC Can't Weigh In On Effexor Authorized Generics Case
- J&J Resolves 5 Risperdal Off-Label Marketing Cases
- AngioDynamics Wins $16.5M Over Biolitec IP Indemnification
- FDA, Interpol Shut Down 18K Illegal Pharmacy Sites
- Case Study: In Re Pom Wonderful
- Reporting Under The Sunshine Act: Still In The Dark
- Apotex Says FDA Botched Plant Evaluation In Drug Approvals
- FDA Device Center Must Take Bigger Risks, Director Says
- HHS Report Gives A Leg Up To Supplement-Wary Lawmakers
- HHS Inspector General Plans New Reviews Of ACA Programs
- Generics Group Urges High Court To Take Pay-For-Delay Case
- Greenberg Traurig Brings Aboard King & Spalding Patent Atty
- Exxon, Lilly, Others Sued Over $21M In Superfund Costs
- Brown Rudnick's Bad Advice Led To $3M Penalty, SOI Says
- FTC 'Green Guides': What The Changes Mean For Marketers
- Sanofi Dismissal Affirmed In Generic Ambien Liability Suit
- US Blasts Cordis' Re-Exam Discovery Bid At Fed. Circ.
- Panel Sends Biomet Hip Implant MDL To Indiana
- Pfizer, King Can't Shake FCA Suit Over Medicaid Rebates
- Strengthening Medical Device Postmarket Surveillance
- ACA, Medicaid Mark Policy Contrast Between Obama, Romney
- Mylan Knocks Ranbaxy's Exclusivity Right For Valsartan
- FDCA Preempts Suit Over Medtronic Pacemaker Death: Judge
- Abbott Labs To Pay $700M In Depakote Criminal Case
- Merck Sues To Block Sandoz's Generic Zetia
- 6th Circ. Upholds Ohio Law Restricting Abortion Pill
- FDA Needs Certain Fundamental Reforms, Obama Adviser Says
- Zimmer Gets FDA Warning Letter Over Implant Manufacturing
- Is Obviousness The New Anticipation?
- FDA Wants Employee Email Spying Suit Dismissed
- Stakes Are High For Companies Negotiating CIAs
- Liberty Targets Drug Provider Over 'Pill Mill' Suit Coverage
- CORRECTED: FTC Pulls Antitrust Probe Over Yasmin Deals
- Medtronic Preemption Case Turned Away By Supreme Court
- $22M Award Won't Stop Cordis' Infringement, Fed. Circ. Told
- Grassley Presses Hospitals On Low-Cost Drug Program
- Roche's Boniva Patent Declared Invalid
- Sanofi Gets Reprieve In Amphastar's Lovenox FCA Suit
- High Court Won't Review Case Over Skelaxin Antitrust Standing
- Device Cos. Take Aim At Tax While Guarding FDA User Fees
- Trustee Urges High Court To Question CMS Payment Decisions
- China's Compulsory Licenses — A Danger To Pharma Patents